Good for today quarter fourth our update XXXX joining and full afternoon. year you for and financial call. us results thank And corporate
I I our have of scourge. to Capricor this encouraging details our on we the at science in get everyone by before move COVID-XX. forward. fight are to affected with that that together what is difficult programs times concern been are like everybody. of globally call, is to But for at these and medicine, this continue coming we Is our spirit course, Of for into all who Capricor, would express behalf those recognize We
XXXX made very we XXXX. are enthusiastic looking with the On that note, ahead, are we progress and that about we've pleased in very
to at a patients technology the committed our Capricor driven and All our to of of lead our of goal disorders. exosome product variety of we to treatment Duchenne are for treat candidate, expanding Dystrophy, platform CAP-XXXX achieve Muscular bringing to us are
are is that light we everything a including important vaccines recent focusing feel for on indications, developing our of variety happening with in this announcement, in of especially COVID-XX. We stated As those origin. now exosomal right of viral
I specific program the building the for on occurred of On platform, a CAP-XXXX a that objectives exosomes with year, DMD, and key vaccine will an XXXX. the today, overview focus for our development during our events and be providing call past goals of the
the the data Muscular investigating six to of interim accomplishments important want XXXX, Dystrophy. to in I a Duchenne of clinical First, July area this our our was audience XXth and the of disease. World trial We XXXX. results revealed at of Muscle CAP-XXXX working International present highlight results were presentation. for breaking positive in delighted We of visibility these trial clinical X CAP-XXXX in months some a significant the HOPE-X neuromuscular Congress experts In increase of of Phase the to professional late Society achievement
on into of Following to we data guidance the with in forward and receipt are with development this C to data, meetings regulatory continue the our discuss the have productive the we and obtain meeting we and a FDA FDA study clinical that strategy. ongoing End-of-Phase our path Type incorporating their met
inception want We in non-dilutive the additional to plan and as million sheet. since we $XX also of funding that they at to XXXX strengthen approximate over company, financing support to $X.X development received available. our I of equity pursue the have completed become end to And an balance we opportunities also capital our million the highlight
in of and X approximately is Briefly, months turn fiber This dystrophin, disease lead the trial. that XX,XXX the XXX,XXX lack muscle as devastating to our muscle number in the is due -- genetic DMD interim disorder and which boys causes genetic our of muscle in six cell. treatment HOPE-X of drug our affects protein Phase biologic let's and young United membrane turn degeneration quickly, our the first-in-class results a men lead that as candidates, States. a investigated CAP-XXXX, acts DMD, a includes This currently Now glue to let's kind being cushion for positive worldwide. clinical a
to The dystrophin XX, complications age of and death make them predisposes to damage of lack muscles commonly degeneration to before properly. the from cardiomyopathy. generally This muscle the unable of function leads most
on who these and a men, typically These there of patients. boys mainly means get ages XX for Our around. and approved primarily are currently no the consists are XX, are Duchenne non-ambulant, between DMD products are participants and wheelchair study which young they to dependent of
an enough care emphasize are for and cannot despite young maintain to arms, their unable I to of day-to-day hands boys work shoulders teeth. brushing challenges these which and taking of effective the walk who use for for dire and themselves, their like therapy activities the needs, basic their includes need hygiene feeding life men their
and young is attempting and every not fight day of many these other stages independence CAP-XXXX do particular boys suffer to the now on these their keep that is reliance And people. the treat. address therapies later this Current it gene of and minimize battle limited disease. a the patients of men patients is to this who from It group are
the the at of in look let's involved technology and positive X the Phase results trial. Now clinical CAP-XXXX,
through to anti you, CAP-XXXX immunomodulatory, remind is therapeutic base is generation has cells. of and to cell muscle lead new candidate, fibrotic, mechanism of action been the me the let Capricor’s First, shown
at the efficacy with regimen three and sites XX.X double placebo skeletal unstable participants cells function. safety trial States. were trial in mean reduce nine Phase every the United a the all trial is The in HOPE-X CAP-XXXX participants The blind, patients were million age trial The and dosing non-ambulant. of to objective intravenously of patients the the of patients delivered XX randomized, controlled muscle DMD XX% with and for in years, of II is months evaluate XXX of corticosteroids
demonstrated upper six saw Data months the elbow results in clinical performance that the advanced function. the and boys II in A hand Phase stages and two of distal teenage men Patients receiving of analysis. interim showed and tool skeletal, and HOPE-X shoulder, young wrist cardiac pulmonary analysis improvements significant for the designed improvements function limb, company assessing the positive DMD the interim doses was specifically milestone from in the a for CAP-XXXX. after of from
in Additionally, assessing the and results. tip-to-tip constraints test, in tests positive grip showed also strength
version Although the biologic as has we primary would a PUL commenced version the the license a endpoint, the known which endpoint, as updated the use support PUL BLA. as X.X primary FDA trial using a our X.X fondly suggested efficacy application, efficacy of
scale performance across the HOPE-X walk PUL upper of measure motor on was is evaluated the also the the severity unable using minute test. focused limb to patients who're We in to designed X DMD spectrum patients perform and The of X.X. PUL specifically
lateral study function of in In this There and function and the pulmonary also anterior MRI, in heart, less an in patients of DMD cardiac In progressively by the observed. an of was in measured the stages heart. later thickening was they with function have so improvement impaired wall improvement as the climbed their disease.
very positive see be possible XX Improving This systolic suggest may wall data. we months improvements better the is for CAP-XXXX. promising understood once thickening data functional that
showing study positive from two and The DMD improvements is shown upper non-ambulant patients. trial, clinical outcomes limb controlled clinical clinical have the HOPE-X functional to-date. first placebo We trials
by have therapy the designation, drug advanced dystrophy. acronym FDA designation the granted designation, RMAT, and known we orphan rare by As for of Duchenne announced, previously medicine disease CAP-XXXX Capricor pediatric muscular treatment has the regenerative been for
to designation plan The designation, the The cells RMAT of of helpful and discuss let more is and goal you, CAP-XXXX. the FDA, meetings FDAs therapies. has FDA eligibility which of is RMAT and designation review facilitate of gene include course in review. development remind frequent development that product to provides the with of the me more efficient the for enabled review rolling The the candidate development priority with closely RMAT to collaborate us benefits and
from We final which awaiting HOPE-X study, months in in the coming this assessments the are of the now undergoing year, results are patients to announce their XX second plan as quarter weeks. we the
next with in to this positive, intend steps of receipt program. meet this if Following to FDA discuss data the the we
to is this as move therapeutic quickly towards as goal Our registration possible.
news the at Johns vaccines chemistry same strategic like of recently the I announced We exosomal-based our Capricor's Hopkins create At our develop Technology. therapeutic expand to and would to on attention expansion time, we Now our of and further therapeutics. platform turn the a Consultants University new biological latest Professor to the appointment to development technology Exosome as Executive manage to plans exosome announced Dr. Gould, our Stephen of initiative. your and direct
very excited importance Gould. step our exosome are about leadership technology the We and platform of the Dr. of under the potential realizing this important
to exosome virus an Dr. was and Capricor’s you spreading. tell is expert Well, development He to unparalleled and mechanistic of brings exosome research understanding between first engineering link bit recognized who Gould���s a reveal let biogenesis an exosome about little Dr. me the exosome-based team the program. Gould. Internationally
The of first first engineering cancer the to therapeutic. mechanisms to develop identify an and exosome exosome-based
has Gould published several organized review and research NIH scientific numerous conferences, reviews an public and received array chapters, book served research other cited and grants, numerous Dr. panels. of and articles and private numerous grant on
membrane I know vesicles cell. be to virtually to Exosomes we've nanometre and exosomes into a modified lipid of composed with secreted bound but cell all therapeutic types bi-layer. while, by can signal been discussing briefly communicate cell a or extracellular are this remind size and you, for are a potentially transport
so to approach, or bring outside, shotgun It importance acids Exosomes of speaks vehicle. the exosome language of to the the a adapted the target nucleic to delivery is how a might highlights drug harnessing inside. better proteins the a as on than power able a on are of interest can also the rather This a which liposome of the therapeutic work. be cell, carry
an why So platform. very question, answer exosomal let this Capricor is developing importantly, vaccine me
majority comprised killed of purified or alive vast agents pathogen and the coding recombinant DNAs. proteins, While or attenuated vaccines of antigen are
advance, who recombinant of many While relatively with killed virus and infection. Well these to attenuated are with produce weak vaccine. both protection risks yields the DNAs effective against viruses, vaccinated immunization provides immunization approaches poses against health those individuals and other often proteins
and combines of of vaccine not for COVID-XX. publicly choosing immunizing say viruses, conventional developing the limitations vaccine we comes the quickly mimics such newly makes vaccine vaccine. approach by the protection as safety technology based a based profile details this the uniform with vaccine. a are improved that absence that But emerging that to a to effective overcome the virus IP vaccines is disclose in from superior concerns, manner exosome difficult these can development Capricor technology working multiple free to Furthermore, advantages individuals platform it develop of with to Due to virus antigens produce our we at of time. exosome
be antigen, the simultaneous in to been through cellular responses exosome patent vaccine platforms projects, help designed other Capricor’s filings. Capricor of indications. vaccines based In exosome early which exosome elicit described designed represent addition, expression multiple are immune efforts has based for will COVID and humoral stage drug which plans research strategy. optimize XX based develop our vaccination to and These to us
will to experimental based approval. which studies, step vaccines, which, produce to COVID of safety with The our and will subject first be be efficacy exosome batches first FDA followed course up be monitoring XX if and successful, will of
are this updates need focused on tuned on have there on great great become for Additionally, remain opportunities of helping many federal as we for announced, and patient. focused agencies recently very from that area stay in we funding they are Please these to opportunities need, grant area actively been as pursue this of plan this non-dilutive available. which
week us join as exosome to infectious Furthermore, cancer. it other target, using I such to vector have development, any Gould in on discuss for whether next vaccine the a of a an disease, unique an be asked or as call opportunity Dr.
times, from the is Lastly, to that challenging the to company ability build it of to assets is note in bedside. important key our these that bench
medicine. working in that conjunction us which Dr. same and science type have building of looking access allowed leaders the his academic our the forward to since to Gould with We're We been laboratory. has relationship the inception, with drives
We will the team here expanding also continue to company's platform. support at to Capricor build our
begin highlight to key XXXX. objectives for I Now looking will our ahead,
the DMD Phase quarter, for we line X continue cell final after top the data. with expect second receipt FDA our and report of program expect this next discuss HOPE-X we DMD, months for study to the in For XX to CAP-XXXX to therapy active data discussions steps program XX DMD months our
on on we exosome-based And focusing now our exosome in platform our focused program, and vaccine are exosome COVID-XX. are developing for an technology expanding
for tuned is it While program, as become available. for days they early still stay this more updates
In an second using to IND DMD for addition, file in we CDC quarter. our plan the exosomes
AJ Finally, now we'll partnership our programs. Bergmann, pursue I over grant of for will that, turn continue call to and to With the CFO. our opportunities each
